CDX-622

Phase 1Small molecule

CCelldex Therapeutics

CDX-622 is one of 22 small molecule programs targeting Asthma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

Moderate AsthmaRecruiting

AsthmaPhase 1

Active, not recruiting

Moderate AsthmaPhase 1

Recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Cinqair

Teva

Preclinical

13 2

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 3

Atrovent

Boehringer Ingelheim

Preclinical

5 4

Arcoxia

Symbicort

6 6

Atrovent

Boehringer Ingelheim

Preclinical

2 7

Aciphex

Akero Therapeutics

Preclinical

2 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 9

Tylenol

KKenvue Brands

Preclinical

1 10

DUPIXENT

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Moderate Asthma

NCT07330778

Clinical

Trials by Indication[1]

Moderate Asthma1 trial

An Open-Label, Single-Dose Study to Assess the Safety, Pharmacodynamics, and Pharmacokinetics of CDX-622 in Adults With Mild to Moderate Asthma

Recruiting·CCelldex Therapeutics·Phase 1·NCT07330778·12 enrolled

Unspecified1 trial

A Phase I Study of CDX-622

Active, not recruiting·CCelldex Therapeutics·Phase 1·NCT06650761·85 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CDX-622. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CDX-622 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CDX-622. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celldex Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCelldex Therapeutics

CDX-622

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Moderate Asthma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News